0%
Print report
Variant interpretation report

CEBPA c.576G>T, p.Pro192=

NM_004364.3:c.576G>T NP_004355.2:p.(Pro192=) Synonymous · exon 1 View identifiers
Classification
Uncertain significance

Variant description:

The CEBPA NM_004364.3:c.576G>T (NP_004355.2:p.(Pro192=)) synonymous variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About CEBPA

CEBPA encodes a transcription factor that turns genes on and off to regulate cell identity, cell-cycle control, and the development of blood, fat, and epithelial cells. It is especially important for myeloid and granulocyte development, and its disruption is associated with acute myeloid leukemia and inherited predisposition to this disease. CEBPA acts as a tumor suppressor by supporting normal differentiation and limiting abnormal cell growth.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% PM2 cutoff, with five alleles and no homozygotes; gnomAD v2.1 is absent.

Benign criteria applied · 1
BP4Supporting
BP4 · supporting

Met at supporting: synonymous-variant SpliceAI max delta 0.003 meets the BP4 threshold of <=0.1.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) and BP4 (supporting) do not independently satisfy any generic pathogenic or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
5 / 1,289,770 alleles

gnomAD v4.1: 5 / 1,289,770 alleles. Recorded AF 3.87666e-06. Recorded homozygote count 0.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.8404392010279176e-05, 1/17122 alleles, homozygotes = 0).

SpliceAI score
0.003 maximum delta

Recorded SpliceAI maximum delta score: 0.003. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
3 reported laboratory submissions

2 Likely benign · 1 Uncertain significance. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 5 not met · 11 not assessed · 10 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No VCEP covers CEBPA in this case; generic ACMG/AMP 2015 rules govern.

PS4 and PP4 are not assessed because the required variant-specific case-control or highly specific phenotype evidence is unavailable.

PP5 and BP6 are not met because ClinVar variation 415192 has no exact-variant expert-panel classification; BP5 is not assessed because no alternate molecular basis is documented.

The variant is synonymous, so PP3 and BP4 are evaluated through the SpliceAI path only; REVEL and BayesDel are not used.

SpliceAI max delta 0.003 supports BP4 but is below the PP3 threshold, so the same prediction is not double-counted across opposing criteria.

BP7 cannot be completed without the required nucleotide-conservation assessment.

Population evidence supports PM2 at Moderate strength because gnomAD v4.1 grpmax FAF is 3.892e-05, below the supplied 0.0001 cutoff, and gnomAD v2.1 is absent.

BA1 and BS1 are not met because the filtering grpmax FAF is far below their respective 0.05 and 0.01 thresholds.

BS2 is not applicable because the required early-onset full-penetrance context and exact-variant healthy-adult observation are not established.

Met · 2

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% PM2 cutoff, with five alleles and no homozygotes; gnomAD v2.1 is absent. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength under the instructed ACMG/AMP 2015 framework. The variant is absent from gnomAD v2.1 and is present only at an extremely low frequency in gnomAD v4.1: AF 3.87666e-06 (5/1,289,770 alleles), zero homozygotes, with grpmax FAF=3.892e-05 (0.003892%). This is below the supplied generic PM2 cutoff of 0.0001 (0.01%). No VCEP-specific population source supersedes the default all-comers source.

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 reports the variant as absent.
  • gnomAD v4.1 reports AF 3.87666e-06 from 5/1,289,770 total alleles, zero homozygotes, and grpmax FAF=3.892e-05 (0.003892%).
  • The supplied generic PM2 cutoff is <=0.0001 (0.01%), and the observed filtering FAF is below that cutoff.
Sources
BP4 SupportingACMGMet at supporting: synonymous-variant SpliceAI max delta 0.003 meets the BP4 threshold of <=0.1. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_004364.3:c.576G>T; p.(Pro192=)), so BP4 uses the SpliceAI path only. SpliceAI max delta is 0.003, which is at or below the supplied BP4 supporting threshold of <=0.1 (Jaganathan et al. 2019, PMID:30661751). This supports no predicted splice impact for the synonymous variant. REVEL is not applicable to this path, and no other predictor is counted. BP4 is met at ACMG/AMP 2015 supporting strength.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • SpliceAI Lookup for NM_004364.3:c.576G>T reports DS_AG=0.000, DS_AL=0.003, DS_DG=0.000, DS_DL=0.001, with max delta score 0.003.
  • For a synonymous variant, the governing generic rule selects the SpliceAI path only; REVEL is not used for this situation.
  • Jaganathan et al. 2019 (PMID:30661751) supplied the generic SpliceAI BP4 supporting cutoff of <=0.1; the observed max delta 0.003 meets it.
  • Richards et al. 2015 (PMID:25741868) defines BP4 as a supporting computational-evidence criterion; no higher strength is applied.
Sources

Not met · 5 · evaluated, threshold not reached

PP3 ACMGNot met: synonymous-variant SpliceAI max delta 0.003 is below the PP3 threshold of >=0.2. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_004364.3:c.576G>T; p.(Pro192=)), so the applicable generic computational path is SpliceAI rather than REVEL. SpliceAI max delta is 0.003, which is below the supplied PP3 supporting threshold of >=0.2 (Jaganathan et al. 2019, PMID:30661751). REVEL is unavailable and is not applicable to this synonymous-variant path; BayesDel has no established generic ACMG-strength calibration and is not used. Therefore PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • SpliceAI Lookup for NM_004364.3:c.576G>T reports DS_AG=0.000, DS_AL=0.003, DS_DG=0.000, DS_DL=0.001, with max delta score 0.003.
  • For a synonymous variant, the governing generic rule selects the SpliceAI path only; REVEL is not used for this situation.
  • Jaganathan et al. 2019 (PMID:30661751) supplied the generic SpliceAI PP3 supporting cutoff of >=0.2; the observed max delta 0.003 does not reach it.
  • Richards et al. 2015 (PMID:25741868) defines PP3 as a supporting computational-evidence criterion; no higher strength is applied.
Sources
PP5 ACMGNot met: ClinVar has 0 expert-panel submissions, and its non-expert Likely benign assertions cannot trigger PP5. Details ▾Hide ▴
Reasoning

PP5 is restricted here to an exact-variant ClinVar expert-panel classification of Pathogenic or Likely pathogenic. ClinVar variation 415192 has zero expert-panel submissions; its conflicting aggregate includes only ordinary laboratory or non-expert assertions, including Likely benign submissions, so PP5 is not met.

Rule
Generic rules for PP5/BP6: apply them only for an exact-variant ClinVar expert-panel classification: Pathogenic/Likely pathogenic supports PP5; Benign/Likely benign supports BP6. Ordinary laboratory submissions, aggregate ClinVar labels, and non-expert assertions must never trigger either criterion.
Evidence considered
  • ClinVar variation 415192, exact variant NM_004364.5(CEBPA):c.576G>T (p.Pro192=): 4 submissions, 0 expert-panel submissions, and no Pathogenic or Likely pathogenic expert-panel classification.
Sources
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 0.003892%, far below the 5% BA1 threshold, despite a South Asian point estimate of 0.01003%. Details ▾Hide ▴
Reasoning

BA1 is not met. The governing generic frequency metric is gnomAD v4.1 grpmax FAF, 3.892e-05 (0.003892%), based on 5/1,289,770 total alleles; this is far below the 0.05 (5%) BA1 threshold. The highest point estimate is South Asian AF 0.000100285 from 5/49,858 alleles, but the required filtering FAF remains below threshold and the qualifying population has more than 2,000 observed alleles. gnomAD v2.1 also reports the variant as absent. The available population data therefore do not support a stand-alone benign frequency call.

Rule
BA1: Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 reports total AF 3.87666e-06 from 5/1,289,770 alleles, zero homozygotes, South Asian AF 0.000100285 from 5/49,858 alleles, and grpmax FAF=3.892e-05.
  • The filtering allele-frequency lower bound is used rather than the South Asian popmax point estimate; its observed-allele count exceeds 2,000.
  • gnomAD v2.1 reports the variant as absent.
Sources
BS1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 0.003892%, below the generic 1% BS1 threshold and therefore does not indicate an excessive disease frequency. Details ▾Hide ▴
Reasoning

BS1 is not met. gnomAD v4.1 grpmax FAF is 3.892e-05 (0.003892%), based on 5/1,289,770 total alleles, which is below the generic 0.01 (1%) BS1 threshold by more than two orders of magnitude. The South Asian point estimate of 0.000100285 is not used for the decision because BS1 requires the filtering grpmax FAF, and it is also well below 1%. No maximum-credible-frequency calculation is needed to reject this frequency-based BS1 call; the observed frequency is not elevated for the generic threshold.

Rule
BS1: Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1 reports grpmax FAF=3.892e-05 (0.003892%) from 5/1,289,770 total alleles; the highest South Asian point estimate is 0.000100285 from 5/49,858 alleles.
  • The generic BS1 default is 0.01 (1%); Whiffin et al. 2017, PMID:28518168, is the cited maximum-credible-frequency framework, but no calculation is required because the observed FAF is far below the default threshold.
  • The qualifying frequency population has more than 2,000 observed alleles, so the filtering FAF is interpretable under the supplied rule.
Sources
BP6 ACMGNot met: ClinVar has 0 expert-panel submissions, so its non-expert Likely benign classifications cannot trigger BP6. Details ▾Hide ▴
Reasoning

BP6 is restricted here to an exact-variant ClinVar expert-panel classification of Benign or Likely benign. ClinVar variation 415192 has zero expert-panel submissions; the Likely benign classifications are ordinary laboratory or non-expert assertions and therefore cannot trigger BP6.

Rule
Generic rules for PP5/BP6: apply them only for an exact-variant ClinVar expert-panel classification: Pathogenic/Likely pathogenic supports PP5; Benign/Likely benign supports BP6. Ordinary laboratory submissions, aggregate ClinVar labels, and non-expert assertions must never trigger either criterion.
Evidence considered
  • ClinVar variation 415192, exact variant NM_004364.5(CEBPA):c.576G>T (p.Pro192=): Likely benign submissions are from clinical laboratories or non-expert submitters, with 0 expert-panel submissions.
Sources

Not assessed · 11 · no assessment recorded

PS2 ACMG_2015Not assessed: no documented affected proband, family-history status, or confirmed maternity and paternity is available for this variant. Details ▾Hide ▴
Reasoning

The available case evidence does not document a proband with the disease, absence of family history, or confirmed maternity and paternity for NM_004364.3:c.576G>T. Therefore, the evidence required to assess PS2 is unavailable.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Still missing
  • Affected proband diagnosis and phenotype documentation
  • Family-history documentation
  • Maternity confirmation
  • Paternity confirmation
PS3 ACMG_2015Not assessed: no variant-specific functional assay was identified, and the only quantitative result was computational SpliceAI prediction (maximum delta score 0.003). Details ▾Hide ▴
Reasoning

NM_004364.3:c.576G>T (CEBPA; NP_004355.2:p.(Pro192=)) has no documented variant-specific, well-established in vitro or in vivo functional assay in the reviewed evidence. The available literature includes only general discussion of possible effects of synonymous substitutions and does not test this variant; SpliceAI is a computational prediction, not a functional study. Therefore, the evidence is insufficient to assess PS3 at any ACMG/AMP 2015 strength.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • The variant is a synonymous CEBPA substitution, NM_004364.3:c.576G>T, predicted to encode NP_004355.2:p.(Pro192=).
  • No reviewed source reports a variant-specific in vitro or in vivo functional assay, clinical diagnostic laboratory validation, assay controls, or reproducibility data for this variant.
  • PMID:31189880, A pan-cancer analysis of synonymous mutations, discusses possible effects of synonymous variants but does not mention CEBPA c.576G>T or provide a variant-specific assay; its direct quote is recorded in paper_findings.
  • SpliceAI reports a maximum delta score of 0.003, which is a computational prediction and does not satisfy the PS3 requirement for functional studies.
Still missing
  • A validated, reproducible in vitro or in vivo assay of CEBPA c.576G>T assessing gene or gene-product function is needed.
Sources
generic_acmg_combination_rulesPMID:25741868 ↗PMID:31189880 ↗
PS4 ACMG_2015Not assessed: no affected-case and control counts, odds ratio, or confidence interval are available to evaluate the PS4 >5.0 and CI-not-including-1.0 requirements. Details ▾Hide ▴
Reasoning

The governing PS4 rule requires significantly increased prevalence in affected individuals compared with controls; ACMG/AMP Note 1 specifies an odds ratio or relative risk >5.0 with a confidence interval that does not include 1.0. The literature_pass packet has no AI-classified PS4 papers, and the only PS4-indexed paper reviewed (PMID:24121147) concerns SERPINA1 alpha-1-antitrypsin deficiency, does not mention CEBPA or NM_004364.3:c.576G>T, and provides no relevant case or control counts. gnomAD reports 5/1,289,770 alleles overall (AF 3.87666e-06), but no affected-case prevalence is available, so an odds ratio and 95% confidence interval cannot be computed and PS4 cannot be assessed.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:24121147 paper extract: the paper concerns SERPINA1 alpha-1-antitrypsin deficiency, does not mention CEBPA or c.576G>T, and provides no relevant case-control cohort.
  • gnomAD v4.1: NM_004364.3:c.576G>T is present at 5/1,289,770 alleles (AF 3.87666e-06), but no affected-case frequency is supplied, so no case-control OR or 95% CI can be calculated.
  • No AI-classified PS4 paper was present in literature_pass.json.
Still missing
  • A variant-specific affected cohort and matched unaffected or population control counts are needed to calculate an odds ratio or relative risk and its 95% confidence interval.
Sources
PM6 ACMG_2015Not assessed: no assumed de novo occurrence or parental testing information is documented for this variant. Details ▾Hide ▴
Reasoning

The available case evidence does not document an assumed de novo occurrence of NM_004364.3:c.576G>T or provide parental testing information. Therefore, PM6 cannot be assessed.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Still missing
  • Evidence that the variant is de novo
  • Parental testing results or documentation that maternity and paternity were unconfirmed
PP1 ACMG_2015Not assessed: no affected relatives, genotypes, or segregation data are documented for this variant. Details ▾Hide ▴
Reasoning

The available case evidence does not report affected family members, genotypes, or family-level segregation data for NM_004364.3:c.576G>T. Consequently, co-segregation and any stronger PP1 level cannot be assessed.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Still missing
  • Affected family-member phenotype information
  • Genotypes of affected family members
  • Number of informative meioses or segregations
PP4 ACMG_2015Not assessed: no patient phenotype or family history is available that demonstrates high specificity for a disease with a single genetic etiology. Details ▾Hide ▴
Reasoning

The governing PP4 rule requires a patient's phenotype or family history highly specific for a disease with a single genetic etiology. The supplied case evidence does not provide a patient phenotype or family history for this variant that can be assessed for that level of specificity; the available phenotype-related paper is unrelated to CEBPA and this exact variant.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • A documented patient phenotype or family history, with its disease-specificity and competing etiologies, is needed.
BS3 ACMG_2015Not assessed: no validated experimental evidence shows that CEBPA c.576G>T preserves protein function or splicing; SpliceAI is computational only. Details ▾Hide ▴
Reasoning

NM_004364.3:c.576G>T (CEBPA; NP_004355.2:p.(Pro192=)) has no documented variant-specific, well-established in vitro or in vivo functional assay showing preserved protein function or normal splicing in the reviewed evidence. The general synonymous-variant literature does not test this variant, and a low SpliceAI score is computational rather than experimental. Therefore, the evidence is insufficient to assess BS3 at any ACMG/AMP 2015 strength.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • The variant is a synonymous CEBPA substitution, NM_004364.3:c.576G>T, predicted to encode NP_004355.2:p.(Pro192=).
  • No reviewed source reports a variant-specific in vitro or in vivo functional assay, validated clinical-laboratory assay, assay controls, or reproducibility data demonstrating normal CEBPA function or splicing for this variant.
  • PMID:31189880, A pan-cancer analysis of synonymous mutations, provides only general background on potential synonymous-variant effects and does not mention CEBPA c.576G>T or test its function or splicing; its direct quote is recorded in paper_findings.
  • SpliceAI reports a maximum delta score of 0.003, but this computational prediction cannot establish the BS3 functional-study requirement.
Still missing
  • A validated, reproducible in vitro or in vivo assay of CEBPA c.576G>T demonstrating no damaging effect on protein function or splicing is needed.
Sources
generic_acmg_combination_rulesPMID:25741868 ↗PMID:31189880 ↗
BS4 ACMG_2015Not assessed: no tested affected relatives lacking the variant are documented, so non-segregation cannot be evaluated. Details ▾Hide ▴
Reasoning

The available case evidence does not identify affected family members who were tested and found not to carry NM_004364.3:c.576G>T. Thus, lack of segregation cannot be assessed.

Rule
Lack of segregation in affected members of a family.
Still missing
  • Identified affected family members
  • Variant-testing results for affected family members
  • Assessment of possible phenocopies or multiple pathogenic variants
BP2 ACMG_2015Not assessed: no documented cis/trans phase result or pathogenic partner variant is available for this synonymous CEBPA variant. Details ▾Hide ▴
Reasoning

BP2 requires observation of the evaluated variant in trans with a pathogenic variant for a fully penetrant dominant disorder or in cis with a pathogenic variant in any inheritance pattern. The available case evidence contains no individual-level phase result, affected-proband observation, or documented pathogenic variant in cis or trans, so BP2 cannot be assessed.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The available case evidence does not document a pathogenic partner variant in cis or trans with NM_004364.3:c.576G>T.
  • No parental, offspring, or other phase-testing result is provided.
Still missing
  • Phase testing and the identity and pathogenic classification of any partner variant are unavailable.
BP5 ACMG_2015Not assessed: no case documents this variant together with a confirmed alternate molecular basis for the relevant disease. Details ▾Hide ▴
Reasoning

The governing BP5 rule requires the variant to be found in a case with an alternate molecular basis for disease. The available evidence does not document an individual carrying NM_004364.3:c.576G>T who has a confirmed alternate molecular cause of the relevant disease, so BP5 cannot be assessed.

Rule
Variant found in a case with an alternate molecular basis for disease.
Still missing
  • A case report or cohort record must document the exact variant and an independently established alternate molecular cause of disease.
BP7 ACMG_2015Not assessed: SpliceAI max delta 0.003 supports no splice impact, but BP7's required nucleotide-conservation assessment is unavailable. Details ▾Hide ▴
Reasoning

BP7 is applicable because NM_004364.3:c.576G>T is a synonymous variant (p.(Pro192=)). The applicable splice-prediction component is satisfied: SpliceAI max delta is 0.003, indicating no predicted splice impact and meeting the supplied no-impact cutoff of <=0.1. However, BP7 also requires that the nucleotide not be highly conserved, and the case evidence does not provide a conservation assessment for c.576. Because this required component is missing, BP7 is not assessed rather than inferred from the SpliceAI result alone.

Rule
A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • The variant is annotated as synonymous: NM_004364.3:c.576G>T, NP_004355.2:p.(Pro192=).
  • SpliceAI Lookup reports max delta score 0.003, below the supplied no-impact cutoff of <=0.1.
  • No nucleotide-conservation result for c.576 is available in the reviewed case evidence, so the second BP7 requirement cannot be evaluated.
  • Richards et al. 2015 (PMID:25741868) defines BP7 as a supporting criterion for synonymous variants requiring both no predicted splice impact and absence of high nucleotide conservation.
Still missing
  • Conservation assessment for the c.576 nucleotide is required to determine whether it is not highly conserved.
Sources
Not applicable · 10· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PS1 N/ANot applicable: PS1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PS1 (Richards et al. 2015, PMID:25741868) requires the same amino acid change as a previously established pathogenic variant, evaluated regardless of the underlying nucleotide change. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, no altered amino acid exists at this position to compare against any previously established pathogenic missense variant, so PS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PS1 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM1 N/ANot applicable: PM1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM1 (Richards et al. 2015, PMID:25741868) applies to a missense variant located in a mutational hot spot and/or a critical, well-established functional domain without benign variation. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, no altered residue exists to evaluate for mutational hot-spot or critical-domain membership, so PM1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM1 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM3 N/ANot applicable: CEBPA familial acute myeloid leukemia is described as autosomal dominant, whereas PM3 is restricted to recessive disorders with confirmed trans phase. Details ▾Hide ▴
Reasoning

PM3 is restricted to recessive disorders and requires the evaluated variant to be detected in trans with a pathogenic variant, with phase established by parental or offspring testing. The case evidence describes CEBPA familial acute myeloid leukemia as an autosomal dominant predisposition and provides no recessive inheritance context; therefore PM3 does not apply.

Rule
For recessive disorders, detected in trans with a pathogenic variant
Evidence considered
  • The case summary describes CEBPA-associated familial acute myeloid leukemia as an autosomal dominant leukemia-predisposition syndrome.
  • No parental or offspring testing establishes this variant in trans with a pathogenic variant in a recessive disorder.
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM5 N/ANot applicable: PM5 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PM5 (Richards et al. 2015, PMID:25741868) requires a novel missense change at an amino acid residue where a different missense change has previously been determined to be pathogenic. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, no missense change exists at this residue to compare against a different pathogenic missense change at the same position, so PM5's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM5 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP2 N/ANot applicable: PP2 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

PP2 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene with a low rate of benign missense variation, where missense variants are a common mechanism of disease. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, the gene's missense-constraint properties are irrelevant because no missense change is present to evaluate, so PP2's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PP2 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BS2 N/ANot applicable: BS2 requires an early-onset, fully penetrant disorder, whereas CEBPA-associated AML has age-dependent penetrance and no exact-variant healthy-adult assessment is documented. Details ▾Hide ▴
Reasoning

BS2 is not applicable on the available evidence. The rule requires observation in a healthy adult for a disorder expected to have full penetrance at an early age. CEBPA-associated familial acute myeloid leukemia is a cancer-predisposition context with age-dependent or variable penetrance, and the population data provide no documented healthy-adult phenotype assessment for this exact variant. gnomAD v4.1 reports zero homozygotes and five total heterozygous alleles, but population inclusion alone does not establish the BS2 requirement.

Rule
BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports zero homozygotes and five total variant alleles, but does not provide a clinical phenotype assessment for the individual carriers.
  • The available case context identifies CEBPA-associated familial acute myeloid leukemia; this is not sufficient to establish full penetrance at an early age for applying BS2.
Still missing
  • No clinical records establish that carriers of this exact variant were healthy adults beyond the expected age of onset.
  • No disease-specific penetrance estimate was available in the reviewed case evidence.
Sources
BP1 N/ANot applicable: BP1 requires a missense variant, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

BP1 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene for which primarily truncating variants are known to cause disease. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, the gene's truncating-variant mechanism is irrelevant because no missense change is present to evaluate, so BP1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP1 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a synonymous variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_004364.3:c.576G>T in CEBPA is a synonymous (silent) substitution predicted to produce NP_004355.2:p.(Pro192=). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for CEBPA, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: synonymous (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules

Identifiers

Gene
CEBPA
Transcript
NM_004364.3
Coding (HGVS c.)
NM_004364.3:c.576G>T
Protein (HGVS p.)
NP_004355.2:p.(Pro192=)
GRCh38
chr19:33301839 C>A
GRCh37
chr19:33792745 C>A
Location and type
Exon 1 · synonymous
ClinVar
415192

Gene diagram

Every interpreted variant in CEBPA, mapped onto the exon structure of NM_004364.3. Select a row to find it on the plot.

CEBPANM_004364.3
Fetching transcript structure from UCSC…
gnomAD v4.1 5 / 1,289,770 alleles AF 3.88e-06 · 0 homozygotes · FAF 3.89e-05
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 3.9e-06 · 5 / 1,289,770 alleles · 0 hom · FAF 3.9e-05
South Asian5 / 49,858 0.0001
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, Ashkenazi Jewish, African/African American, European (non-Finnish).

gnomAD-Canada

AF not recorded · ? / ? alleles

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.87666e-06; MAF= 0.00039%, 5/1289770 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 0.000100285; MAF= 0.01003%, 5/49858 alleles, homozygotes = 0); grpmax FAF= 3.892e-05.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.8404392010279176e-05, 1/17122 alleles, homozygotes = 0).

Open the gnomAD-Canada detail page →

SpliceAI and Pangolin

SpliceAI acceptor lossat -46 bp
0.003
SpliceAI acceptor gainat -88 bp
0.000
SpliceAI donor lossat -363 bp
0.001
SpliceAI donor gainat +139 bp
0.000

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

BP4 SupportingACMGMet at supporting: synonymous-variant SpliceAI max delta 0.003 meets the BP4 threshold of <=0.1. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_004364.3:c.576G>T; p.(Pro192=)), so BP4 uses the SpliceAI path only. SpliceAI max delta is 0.003, which is at or below the supplied BP4 supporting threshold of <=0.1 (Jaganathan et al. 2019, PMID:30661751). This supports no predicted splice impact for the synonymous variant. REVEL is not applicable to this path, and no other predictor is counted. BP4 is met at ACMG/AMP 2015 supporting strength.

Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
  • SpliceAI Lookup for NM_004364.3:c.576G>T reports DS_AG=0.000, DS_AL=0.003, DS_DG=0.000, DS_DL=0.001, with max delta score 0.003.
  • For a synonymous variant, the governing generic rule selects the SpliceAI path only; REVEL is not used for this situation.
  • Jaganathan et al. 2019 (PMID:30661751) supplied the generic SpliceAI BP4 supporting cutoff of <=0.1; the observed max delta 0.003 meets it.
  • Richards et al. 2015 (PMID:25741868) defines BP4 as a supporting computational-evidence criterion; no higher strength is applied.
Sources
PP3 ACMGNot met: synonymous-variant SpliceAI max delta 0.003 is below the PP3 threshold of >=0.2. Details ▾Hide ▴
Reasoning

The variant is synonymous (NM_004364.3:c.576G>T; p.(Pro192=)), so the applicable generic computational path is SpliceAI rather than REVEL. SpliceAI max delta is 0.003, which is below the supplied PP3 supporting threshold of >=0.2 (Jaganathan et al. 2019, PMID:30661751). REVEL is unavailable and is not applicable to this synonymous-variant path; BayesDel has no established generic ACMG-strength calibration and is not used. Therefore PP3 is not met.

Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
  • SpliceAI Lookup for NM_004364.3:c.576G>T reports DS_AG=0.000, DS_AL=0.003, DS_DG=0.000, DS_DL=0.001, with max delta score 0.003.
  • For a synonymous variant, the governing generic rule selects the SpliceAI path only; REVEL is not used for this situation.
  • Jaganathan et al. 2019 (PMID:30661751) supplied the generic SpliceAI PP3 supporting cutoff of >=0.2; the observed max delta 0.003 does not reach it.
  • Richards et al. 2015 (PMID:25741868) defines PP3 as a supporting computational-evidence criterion; no higher strength is applied.
Sources
BP7 ACMG_2015Not assessed: SpliceAI max delta 0.003 supports no splice impact, but BP7's required nucleotide-conservation assessment is unavailable. Details ▾Hide ▴
Reasoning

BP7 is applicable because NM_004364.3:c.576G>T is a synonymous variant (p.(Pro192=)). The applicable splice-prediction component is satisfied: SpliceAI max delta is 0.003, indicating no predicted splice impact and meeting the supplied no-impact cutoff of <=0.1. However, BP7 also requires that the nucleotide not be highly conserved, and the case evidence does not provide a conservation assessment for c.576. Because this required component is missing, BP7 is not assessed rather than inferred from the SpliceAI result alone.

Rule
A synonymous variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.
Evidence considered
  • The variant is annotated as synonymous: NM_004364.3:c.576G>T, NP_004355.2:p.(Pro192=).
  • SpliceAI Lookup reports max delta score 0.003, below the supplied no-impact cutoff of <=0.1.
  • No nucleotide-conservation result for c.576 is available in the reviewed case evidence, so the second BP7 requirement cannot be evaluated.
  • Richards et al. 2015 (PMID:25741868) defines BP7 as a supporting criterion for synonymous variants requiring both no predicted splice impact and absence of high nucleotide conservation.
Still missing
  • Conservation assessment for the c.576 nucleotide is required to determine whether it is not highly conserved.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

7 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine.
    Edwards JG et al. · 2015
    No paper-specific finding is recorded.
    PMID 25730230 ↗
  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    The paper presents general ACMG/AMP standards for interpreting sequence variants and does not mention CEBPA c.576G>T or NP_004355.2:p.(Pro192=); it supplies the governing PS3 and BS3 definitions but no variant-specific functional evidence.
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    The variant classification approach described in this paper is meant to be applicable to variants in all Mendelian genes

    Introduction; Proposed Criteria for Interpretation of Sequence Variants

  • Appropriateness of newborn screening for &#x3b1;1-antitrypsin deficiency.
    Teckman J et al. · 2014
    This paper does not mention CEBPA or the exact variant c.576G>T / NP_004355.2:p.(P192=). It concerns alpha-1-antitrypsin deficiency caused by variants in SERPINA1, particularly the homozygous Z allele, and discusses newborn screening, disease risk, and screening infrastructure; it provides no variant-specific or CEBPA-specific case-control or phenotype evidence.
    Does not name this variant
    PMID 24121147 ↗
    Quoted passage
    α-1-Antitrypsin (AAT) deficiency is a metabolic-genetic disease that, in its classical and most typical form, is caused by homozygosity for the AAT mutant Z gene (SERPINA1).

    Introduction, first paragraph

  • Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.
    Langer A et al. · 2012
    No paper-specific finding is recorded.
    PMID 22947299 ↗
  • Including the initial newborn screening bloodspot collection device serial number on birth certificates: basis and recommendations from the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children.
    Therrell BL et al. · 2013
    No paper-specific finding is recorded.
    PMID 23037933 ↗
  • Parental permission for pilot newborn screening research: guidelines from the NBSTRN.
    Botkin JR et al. · 2014
    No paper-specific finding is recorded.
    PMID 24394680 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 3.87666e-06; MAF= 0.00039%, 5/1289770 alleles, homozygotes = 0) and has highest observed frequency in the South Asian population (AF= 0.000100285; MAF= 0.01003%, 5/49858 alleles, homozygotes = 0); grpmax FAF= 3.892e-05.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

This variant is present in gnomAD-Canada v1.0 (AF= 5.8404392010279176e-05, 1/17122 alleles, homozygotes = 0).

ClinVar

This variant has been reported in ClinVar as Likely benign (2 clinical laboratories) and as Uncertain significance (1 clinical laboratory). (ClinVarID = 415192)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

Functional

OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.